1. Home
  2. OI vs RCKT Comparison

OI vs RCKT Comparison

Compare OI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$9.89

Market Cap

2.3B

ML Signal

HOLD

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

HOLD

Current Price

$4.22

Market Cap

534.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
RCKT
Founded
1903
1999
Country
United States
United States
Employees
N/A
202
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
534.2M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
OI
RCKT
Price
$9.89
$4.22
Analyst Decision
Buy
Buy
Analyst Count
7
14
Target Price
$17.57
$29.65
AVG Volume (30 Days)
2.3M
2.8M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,426,000,000.00
N/A
Revenue This Year
$3.07
N/A
Revenue Next Year
$1.83
$97.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.23
$2.19
52 Week High
$16.91
$8.80

Technical Indicators

Market Signals
Indicator
OI
RCKT
Relative Strength Index (RSI) 21.39 46.17
Support Level N/A $4.16
Resistance Level $13.19 $4.51
Average True Range (ATR) 0.51 0.34
MACD -0.12 -0.11
Stochastic Oscillator 0.62 4.26

Price Performance

Historical Comparison
OI
RCKT

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: